Administration of Rg100204, an aquaporin-9 (AQP9) inhibitor, reduced pancreatic and lung damage in animals with AP by interacting with the NF-κB and Nrf2 pathways and thus suppressing NLRP3 activation [99]. This evidence concerns the gene NLRP3 and alkaline phosphatase measurement.